Serotonin transporter-blocking properties of nefazodone assessed by measurement of platelet serotonin.

Article Details

Citation

Copy to clipboard

Narayan M, Anderson G, Cellar J, Mallison RT, Price LH, Nelson JC

Serotonin transporter-blocking properties of nefazodone assessed by measurement of platelet serotonin.

J Clin Psychopharmacol. 1998 Feb;18(1):67-71.

PubMed ID

9472845 [ View in PubMed

]

Abstract

This study aims to determine whether the newly introduced serotonin type 2 (5-HT2) antagonist nefazodone has serotonin (5-HT) transporter-blocking properties at clinical doses in depressed patients. Change in platelet 5-HT was used as an index of the cumulative peripheral 5-HT uptake blockade produced by nefazodone and selective serotonin reuptake inhibitors (SSRIs). Platelet 5-HT was measured before and during treatment with nefazodone (N = 6) or an SSRI (N = 10) in patients with major depression. Corresponding Hamilton Rating Scale for Depression (HAM-D) scores were also obtained over the course of the study. The results of the study demonstrated that the decrease from mean baseline platelet 5-HT after SSRI treatment was significantly greater than the change after nefazodone treatment (-88% vs. -3%; Mann-Whitney U-test, p = 0.0002). Pretreatment platelet 5-HT level, posttreatment platelet 5-HT level, nor the percent decrease in platelet 5-HT correlated with the percent change in HAM-D scores in either treatment group. In conclusion, therapeutic doses of nefazodone do not cause sustained 5-HT uptake inhibition at the platelet 5-HT transporter.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Nefazodone	Sodium-dependent serotonin transporter	Protein	Humans	Yes	Inhibitor	Details